Corgentech Announces Appointment of Susan Kramer as Vice President of Preclinical Development

May 30, 2006, 01:00 ET from Corgentech Inc.

    SOUTH SAN FRANCISCO, Calif., May 30 /PRNewswire-FirstCall/ --
 Corgentech Inc. (Nasdaq:   CGTK) today announced the appointment of Susan
 Kramer, Dr.P.H. as vice president of preclinical development.
     "Susan's more than 20 years of leading research, preclinical and
 clinical development programs will be instrumental in providing robust
 support for our future clinical programs and advancement of pain products
 into our development pipeline," said John P. McLaughlin, chief executive
 officer of Corgentech.
     Dr. Kramer joins Corgentech from BAS Medical, where she was a
 co-founder and served as vice president of research and development from
 2003 to 2006. She was instrumental in the initiation of the company's
 preclinical and clinical programs. Prior to BAS Medical, Dr. Kramer worked
 at Genentech for 18 years in a number of roles of increasing management
 responsibility, including director of product development, senior director
 of bioanalytical technology and ultimately as senior director of
 development sciences operations and strategic planning. She served as
 project team leader for products Actimmune(R) and Raptiva(R). She led
 numerous pharmacology teams and served on several key committees, including
 the Product Development Committee.
     Prior to Genentech, Dr. Kramer served as the director of Medical
 Laboratories in Montes Claros, Minas Gerais, Brazil as a Peace Corps
 Volunteer, followed by a stint as head of the clinical virology laboratory
 at the UCSF Medical Center at the onset of the AIDS epidemic. Dr. Kramer
 holds Dr.P.H. and M.P.H. degrees in Biomedical Sciences from the University
 of California, Berkeley.
     About Corgentech
     Corgentech is a late-stage biopharmaceutical company that seeks to be
 the leader in the development and commercialization of novel therapeutic
 treatments for pain. The company has four drug candidates in clinical
 development for multiple potential indications, the most advanced of which,
 3268, has completed Phase 3 clinical trials. To reflect the company's core
 focus on novel pain management therapies, the board of directors recently
 voted to change the company name to Anesiva. If approved by stockholders at
 the annual meeting on June 21, 2006, the name change will become effective
 immediately thereafter. Corgentech is based in South San Francisco, CA.
     Forward Looking Statements
     This press release includes "forward-looking statements" within the
 meaning of the safe harbor provisions of the United States Private
 Securities Litigation Reform Act of 1995. Words such as "expect,"
 "estimate," "project," "budget," "forecast," "anticipate," "intend,"
 "plan," "may," "will," "could," "should," "believes," "predicts,"
 "potential," "continue," and similar expressions are intended to identify
 such forward-looking statements. Forward-looking statements in this press
 release include, without limitation, projected timing of clinical
 development and other matters that involve known and unknown risks,
 uncertainties and other factors that may cause actual results, levels of
 activity, performance or achievements to differ materially from results
 expressed or implied by this press release. Such risk factors include,
 among others: whether Corgentech can successfully develop new products and
 the degree to which these gain market acceptance. Actual results may differ
 materially from those contained in the forward-looking statements in this
 press release. Additional information concerning these and other risk
 factors is contained in Corgentech's quarterly report on Form 10-Q for the
 quarter ended March 31, 2006.
     Corgentech undertakes no obligation and does not intend to update these
 forward-looking statements to reflect events or circumstances occurring
 after this press release. You are cautioned not to place undue reliance on
 these forward-looking statements, which speak only as of the date of this
 press release. All forward-looking statements are qualified in their
 entirety by this cautionary statement.

SOURCE Corgentech Inc.